BUDGET IMPACT ANALYSIS OF FIRST-LINE TREATMENT FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

被引：0
|
作者：
Sanchez-de la Rosa, R. [1 ]
Sabater, E. [2 ]
Casado, M. A. [3 ]
机构：
[1] TEVA Pharma SLU, Madrid, Spain
[2] Pharmacoecon & Outcomes Res Iberia, Pozuelo, Spain
[3] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.477
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A319 / A319
页数：1
相关论文
共 50 条
  • [1] Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain
    Sanz-Granda, Angel
    Garcia-Jurado, Laura
    Polanco-Sanchez, Carlos
    [J]. REVISTA DE NEUROLOGIA, 2012, 54 (07) : 446 - 447
  • [2] Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain
    Sanchez-De la Rosa, Rainel
    Sabater, Eliazar
    Casado, Miguel A.
    [J]. REVISTA DE NEUROLOGIA, 2011, 53 (03) : 129 - 138
  • [3] Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain Reply
    Sanchez-De la Rosa, Rainel
    Sabater, Eliazar
    Casado, Miguel A.
    [J]. REVISTA DE NEUROLOGIA, 2012, 54 (07) : 447 - 448
  • [4] BUDGETARY IMPACT OF THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Garcia-Ruiz, A. J.
    Izquierdo Ayuso, G.
    Garcia-Agua Soler, N.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A548 - A548
  • [5] Predictors of first-line treatment persistence in a portuguese cohort of relapsing-remitting multiple sclerosis
    Correia, I.
    Batista, S.
    Marques, I.
    Tabuas-Pereira, M.
    Gouveia, A.
    Parra, J.
    Nunes, C.
    Macario, M. C.
    Cunha, L.
    Sousa, L.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 821 - 821
  • [6] Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis
    Correia, Ines
    Marques, Ines Bras
    Sousa, Mario
    Batista, Sonia
    Ferreira, Rogerio
    Nunes, Carla
    Macario, Carmo
    Cunha, Luis
    Sousa, Livia
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2016, 33 : 73 - 78
  • [7] ALEMTUZUMAB BUDGET IMPACT ANALYSIS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE US
    Celestin, C.
    Wandstrat, T.
    Coleman, C., I
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A280 - A280
  • [8] Course of therapy in patients with active relapsing-remitting multiple sclerosis despite first-line treatment
    Bartosik-Psujek, Halina
    Adamczyk-Sowa, Monika
    Kulakowska, Alina
    Glazewska, Joanna
    Smaga, Anna
    Brola, Waldemar
    [J]. POSTEPY PSYCHIATRII I NEUROLOGII, 2023, 32 (02): : 59 - 67
  • [9] Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis
    Koch, Marcus W.
    Mostert, Jop
    Repovic, Pavle
    Bowen, James D.
    Wolinsky, Jerry S.
    Lublin, Fred D.
    Strijbis, Eva
    Cutter, Gary
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (04) : 1106 - 1116
  • [10] Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis
    Aungsumart, Saharat
    Turongkaravee, Saowalak
    Youngkong, Sitaporn
    Apiwattanakul, Metha
    Thakkinstian, Ammarin
    Chaikledkaew, Usa
    [J]. BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
12345